Skip to main content
Premium Trial:

Request an Annual Quote

Two For One: Mar 16, 2011


A team led by Christian Doerig at Ecole Polytechnique Fédérale de Lausanne and Wellcome Trust Centre for Molecular Parasitology found that a class of chemotherapy drugs also targets the parasite behind malaria. Doerig and his team report in Cellular Microbiology that a Plasmodium falciparum infection stimulates the host erythrocyte signaling pathway that includes MEK1 and PAK1 and that specific allosteric inhibitors of the MEK and PAK enzymes blocks the proliferation of P. falciparum. "The finding that allosteric MEK and PAK inhibitors have parasiticidal activity has considerable implications in strategies for antimalarial drug discovery," the authors write. "Several protein kinase inhibitors have reached the market, mostly as anticancer agents ... and MAPK pathway components (notably MEKs) are considered as attractive targets for cancer chemotherapy."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.